严重难以控制的哮喘采用奥玛珠单抗治疗7年的临床疗效
2011/05/12
摘要
原理：严重哮喘表现为尽管采用大剂量的激素治疗，症状控制仍然不佳，而且存在较为严重的支气管炎症。奥玛珠单抗为重组人源化抗IgE单克隆抗体，是严重过敏性哮喘的一个新治疗药物。
目的：本试验旨在评价长期奥玛珠单抗治疗是否能改善严重哮喘患者的临床控制。
方法：对7名采用奥玛珠单抗与其他药物治疗7年的严重过敏性哮喘患者进行评价，研究奥玛珠单抗对哮喘转归的影响。分析奥玛珠单抗治疗前后的哮喘恶化次数、抗菌药物的使用、其他哮喘治疗药物（全身激素、雾化激素和支气管扩张剂）及肺活量等。
结果：研究的所有对象均能很好的耐受奥玛珠单抗。患者的FEV1和FEV1/FVC得到了改善，症状评分、哮喘恶化次数、使用抗菌药物、雾化吸入激素、支气管扩张剂及口服皮质激素等均呈现下降。治疗4年后上述指标明显改善，治疗7年后改善更为显著。
结论：采用奥玛珠单抗长期治疗，能改善严重哮喘患者的哮喘临床转归。
（林江涛 审校）
J Asthma. 2011 Mar 11. [Epub ahead of print]
Clinical Benefits of 7 Years of Treatment with Omalizumab in Severe Uncontrolled Asthmatics.
Pace E, Ferraro M, Bruno A, Chiappara G, Bousquet J, Gjomarkaj M.
Institute of Biomedicine and Molecular Immunology, National Research Council, Palermo, Italy.
Abstract
Rationale. Severe asthma is characterized by inadequate symptom control and by high rate of inflammation despite high doses of steroids. Omalizumab, a recombinant humanized monoclonal anti-IgE, provides a new therapeutic strategy in severe allergic asthma.
Aims. This study was aimed to assess whether long-term treatment with omalizumab improved clinical control in severe asthmatics.
Methods. We investigated omalizumab effects on asthma outcomes evaluating seven severe allergic asthmatic patients who were treated for 7 years with add-on omalizumab. Number of exacerbations, use of antibiotics, additional asthma medications (systemic steroids, nebulized steroids and bronchodilators), and spirometry were analyzed before and after omalizumab treatment.
Results. Omalizumab was well tolerated by all the studied patients. It improved FEV1 and FEV1/FVC ratio and reduced symptom score, asthma exacerbations, use of antibiotics, and use of nebulized steroids, bronchodilators, and oral corticosteroids. These effects were evident after 4 years of treatment and more pronounced after 7 years of treatment. Conclusions. This study underlines the utility of a long-term treatment with omalizumab to improve asthma clinical outcomes in severe asthmatics.
J Asthma. 2011 Mar 11. [Epub ahead of print]
原理：严重哮喘表现为尽管采用大剂量的激素治疗，症状控制仍然不佳，而且存在较为严重的支气管炎症。奥玛珠单抗为重组人源化抗IgE单克隆抗体，是严重过敏性哮喘的一个新治疗药物。
目的：本试验旨在评价长期奥玛珠单抗治疗是否能改善严重哮喘患者的临床控制。
方法：对7名采用奥玛珠单抗与其他药物治疗7年的严重过敏性哮喘患者进行评价，研究奥玛珠单抗对哮喘转归的影响。分析奥玛珠单抗治疗前后的哮喘恶化次数、抗菌药物的使用、其他哮喘治疗药物（全身激素、雾化激素和支气管扩张剂）及肺活量等。
结果：研究的所有对象均能很好的耐受奥玛珠单抗。患者的FEV1和FEV1/FVC得到了改善，症状评分、哮喘恶化次数、使用抗菌药物、雾化吸入激素、支气管扩张剂及口服皮质激素等均呈现下降。治疗4年后上述指标明显改善，治疗7年后改善更为显著。
结论：采用奥玛珠单抗长期治疗，能改善严重哮喘患者的哮喘临床转归。
（林江涛 审校）
J Asthma. 2011 Mar 11. [Epub ahead of print]
Clinical Benefits of 7 Years of Treatment with Omalizumab in Severe Uncontrolled Asthmatics.
Pace E, Ferraro M, Bruno A, Chiappara G, Bousquet J, Gjomarkaj M.
Institute of Biomedicine and Molecular Immunology, National Research Council, Palermo, Italy.
Abstract
Rationale. Severe asthma is characterized by inadequate symptom control and by high rate of inflammation despite high doses of steroids. Omalizumab, a recombinant humanized monoclonal anti-IgE, provides a new therapeutic strategy in severe allergic asthma.
Aims. This study was aimed to assess whether long-term treatment with omalizumab improved clinical control in severe asthmatics.
Methods. We investigated omalizumab effects on asthma outcomes evaluating seven severe allergic asthmatic patients who were treated for 7 years with add-on omalizumab. Number of exacerbations, use of antibiotics, additional asthma medications (systemic steroids, nebulized steroids and bronchodilators), and spirometry were analyzed before and after omalizumab treatment.
Results. Omalizumab was well tolerated by all the studied patients. It improved FEV1 and FEV1/FVC ratio and reduced symptom score, asthma exacerbations, use of antibiotics, and use of nebulized steroids, bronchodilators, and oral corticosteroids. These effects were evident after 4 years of treatment and more pronounced after 7 years of treatment. Conclusions. This study underlines the utility of a long-term treatment with omalizumab to improve asthma clinical outcomes in severe asthmatics.
J Asthma. 2011 Mar 11. [Epub ahead of print]
上一篇：
与丙酸氟替卡松相比，哮喘患者采用糠酸莫米松吸入治疗能降低短效β2受体激动剂的使用，增加治疗依从性
下一篇：
年龄因素对儿童哮喘严重恶化风险和哮喘控制的影响
